500 Loaves Prepared with Professional Bakers Delivered to Underprivileged Community Members
Part of the Hellow CSR Campaign: “Fostering a Sustainable Culture of Giving”
Alvogen Korea, the Korean branch of global pharmaceutical company Alvogen (CEO: Lee Jun-soo), carried out a “Bread Sharing” volunteer activity on May 23 in collaboration with the Gangnam branch of the Korean Red Cross to commemorate Family Month.
Fifteen employees from Alvogen Korea voluntarily participated in the event, baking and packaging a total of 500 loaves—including cranberry muffins and walnut madeleines—under the guidance of professional bakers. The freshly made bread was then delivered to individuals in welfare blind spots, such as local child meal centers, senior care facilities, and families receiving basic social support, reflecting the company’s commitment to community care.
One participating employee shared, “It was truly heartwarming to know that the bread we prepared with care could brighten someone’s day. I look forward to continuing to take part in these meaningful activities.”
This initiative is part of Alvogen Korea’s Hellow CSR campaign, launched in 2015. The program aims to support the balanced growth and healthy eating habits of children and adolescents while contributing to obesity prevention. The Hellow brand embodies Alvogen Korea’s “Better Planet” vision, symbolizing the company’s commitment to helping build a healthier society—just as warm sunshine brightens our lives.
Lee Dong-han, CSR Manager at Alvogen Korea and organizer of the event, stated, “The Bread Sharing activity provided employees with an opportunity to bring warmth to the tables of their neighbors. Through diverse volunteer efforts, we aim not only to fulfill corporate responsibility but also to establish a sustainable corporate culture that grows together with the local community.”
Alvogen Korea embraces a corporate culture that views social issues as shared challenges and works collaboratively to identify and implement practical solutions. The company will continue building a sustainable giving ecosystem through community-based volunteer activities and CSR programs supporting children, adolescents, seniors, and other vulnerable groups.
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness.
Yihsuan Kuo, Investor Relations Assistant Manager
Jeffrey Tsang, Head of Investor Relations and Corporate Communications
+886 2 2700 5908
investor@lotuspharm.com
